Pharmaceuticals & healthcare
Pfizer and UCB, 2016
We achieved a substantial victory for Pfizer and UCB at trial inside a Hatch-Waxman patent situation against Mylan in regards to the drug Toviaz, which UCB developed and licensed to Pfizer, which markets the drug within the U . s . States. Toviaz generates roughly US$200 million in annual US sales. The current 4 day trial was against Mylan before Judge Gregory Sleet within the District of Delaware. Mylan claimed it would present more powerful invalidity arguments than individuals elevated within the prior situation, however the Court found Mylan’s theories unconvincing considering the persuasive and credible testimony from your chemistry experts. In the close of evidence, Judge Sleet issued an uncommon general verdict in the bench in support of our clients on all five patents, concluding that Mylan unsuccessful to provide a prima facie situation of invalidity. The Court’s decision confirms that no generic will get final Food and drug administration approval to promote a normal form of Toviaz until 2022.
Anthem, Corporation., US$54.2 billion purchase of Cigna Corporation, 2015
We symbolized Anthem, Corporation., among the nation’s largest health advantages companies, in the US$54.2 billion agreement to get Cigna Corporation, a mixture and build a premiere health advantages company with critical diversification and scale to guide the transformation of healthcare delivery for consumers.
Pfizer Corporation., ongoing
We represent Pfizer on the wide range of ip matters: patent violation cases, cases involving antitrust claims according to patent settlements, and cases accusing Pfizer of copyright violation. We conduct US clearance investigations associated with branding of future US products.
We achieved a substantial victory for Pfizer Corporation. and it is co-complaintant Northwestern College within their patent violation litigation against multiple generic drug companies involving patents covering Pfizer’s blockbuster drug LYRICA® and clear on its therapeutic uses.
Within an antitrust situation (according to settlement of the patent situation) relating to the largest-selling pharmaceutical product ever, LIPITOR (US$125 billion each year), the trial court granted our motion to dismiss with prejudice in the whole.
UCB, ongoing
We represent UCB, a Belgium-based, global biopharma company, in US patent violation cases. A current significant victory, upheld through the US Court of Appeals for that Federal Circuit, involved protecting UCB against patent violation claims introduced by Apotex, a normal drug manufacturer, in america District Court for that Southern District of Florida. Following a three-day bench trial on mostly equitable claims, a legal court held that Apotex’s patent was unenforceable, additionally with other decisions favorable to UCB.
Sandoz, ongoing
We represent Sandoz, a significant pharmaceutical manufacturer, within the lengthy-running Average Wholesale Prices (AWP) litigation, that has incorporated numerous federal and condition proceedings introduced by condition Attorneys General along with a qui tam relator alleging false claims act, fraud and consumer protection claims. Plaintiffs declare that pharmaceutical manufacturers reported false and inflated prices, which allegedly caused condition State medicaid programs agencies to pay too much for prescription medications. We achieved significant wins within the two actions litigated to completion when, in every instance, the appellate court reversed substantial jury verdicts for that complaintant condition and issued a judgment in support of Sandoz. These appellate victories combined to reverse greater than US$100 million in judgments and hang important precedents. Our counsel to Sandoz is ongoing.
Hikma Pharmaceuticals PLC, US$2.65 billion purchase of generic drugs companies, 2015
We symbolized Hikma Pharmaceuticals PLC in the US$2.65 billion acquisition of america-based generic drugs companies, Roxane Laboratories and Boehringer Ingelheim Roxane, from German drug maker Boehringer Ingelheim.
Pfizer and UCB, 2016
We achieved a substantial victory for Pfizer and UCB at trial inside a Hatch-Waxman patent situation against Mylan in regards to the drug Toviaz, which UCB developed and licensed to Pfizer, which markets the drug within the U . s . States. Toviaz generates roughly US$200 million in annual US sales. The current 4 day trial was against Mylan before Judge Gregory Sleet within the District of Delaware. Mylan claimed it would present more powerful invalidity arguments than individuals elevated within the prior situation, however the Court found Mylan’s theories unconvincing considering the persuasive and credible testimony from your chemistry experts. In the close of evidence, Judge Sleet issued an uncommon general verdict in the bench in support of our clients on all five patents, concluding that Mylan unsuccessful to provide a prima facie situation of invalidity. The Court’s decision confirms that no generic will get final Food and drug administration approval to promote a normal form of Toviaz until 2022.
Anthem, Corporation., US$54.2 billion purchase of Cigna Corporation, 2015
We symbolized Anthem, Corporation., among the nation’s largest health advantages companies, in the US$54.2 billion agreement to get Cigna Corporation, a mixture and build a premiere health advantages company with critical diversification and scale to guide the transformation of healthcare delivery for consumers.
Pfizer Corporation., ongoing
We represent Pfizer on the wide range of ip matters: patent violation cases, cases involving antitrust claims according to patent settlements, and cases accusing Pfizer of copyright violation. We conduct US clearance investigations associated with branding of future US products.
We achieved a substantial victory for Pfizer Corporation. and it is co-complaintant Northwestern College within their patent violation litigation against multiple generic drug companies involving patents covering Pfizer’s blockbuster drug LYRICA® and clear on its therapeutic uses.
Within an antitrust situation (according to settlement of the patent situation) relating to the largest-selling pharmaceutical product ever, LIPITOR (US$125 billion each year), the trial court granted our motion to dismiss with prejudice in the whole.
UCB, ongoing
We represent UCB, a Belgium-based, global biopharma company, in US patent violation cases. A current significant victory, upheld through the US Court of Appeals for that Federal Circuit, involved protecting UCB against patent violation claims introduced by Apotex, a normal drug manufacturer, in america District Court for that Southern District of Florida. Following a three-day bench trial on mostly equitable claims, a legal court held that Apotex’s patent was unenforceable, additionally with other decisions favorable to UCB.
Sandoz, ongoing
We represent Sandoz, a significant pharmaceutical manufacturer, within the lengthy-running Average Wholesale Prices (AWP) litigation, that has incorporated numerous federal and condition proceedings introduced by condition Attorneys General along with a qui tam relator alleging false claims act, fraud and consumer protection claims. Plaintiffs declare that pharmaceutical manufacturers reported false and inflated prices, which allegedly caused condition State medicaid programs agencies to pay too much for prescription medications. We achieved significant wins within the two actions litigated to completion when, in every instance, the appellate court reversed substantial jury verdicts for that complaintant condition and issued a judgment in support of Sandoz. These appellate victories combined to reverse greater than US$100 million in judgments and hang important precedents. Our counsel to Sandoz is ongoing.
Hikma Pharmaceuticals PLC, US$2.65 billion purchase of generic drugs companies, 2015
We symbolized Hikma Pharmaceuticals PLC in the US$2.65 billion acquisition of america-based generic drugs companies, Roxane Laboratories and Boehringer Ingelheim Roxane, from German drug maker Boehringer Ingelheim.
Zimmer Holdings, US$13.35 billion purchase of Biomet, 2014
We represent Zimmer Holdings, Corporation., a global leader in musculoskeletal health solutions, in the US$13.35 billion purchase of Biomet, Corporation., among the world’s leading medical device manufacturers.
Shenzhen Hepalink, acquisition of Scientific Protein Laboratories, 2014
We symbolized Shenzhen Hepalink Pharmaceutical Co., Limited., a Chinese company on the Shenzhen Stock Market, and it is US subsidiary, Hepalink USA Corporation., in the US$337.5 million purchase of Scientific Protein Laboratories, LLC, one of the main global independent manufacturers and suppliers of active pharmaceutical ingredients. This transaction is among a couple of acquisitions with a People’s Republic of China public company of the US independently held target and constituted a significant reorganization for the client pursuant towards the relevant Chinese listing rules, using the participation of multiple consultants and agencies in america and China.
Wellpoint, Corporation., sale of just one-800 CONTACTS, 2014
We symbolized WellPoint, Corporation., among the nation’s largest health advantages companies, in the purchase of their 1-800 Contacts subsidiary to personal equity firm Thomas H. Lee Partners and it is related asset purchase of just one-800’s glasses.com business to worldwide optical conglomerate Luxottica.
Componen Pharmaceuticals and Paddock Holdings
We symbolized Componen Pharmaceuticals and Paddock Holdings inside a Ftc (Federal trade commission) challenge to settlement contracts regarding AndroGel®. The Eleventh Circuit forcefully reaffirmed the key that brand-generic patent settlement contracts aren’t actionable if they don’t exceed the scope from the patent, handing the Federal trade commission its first “payment for delay” loss on the motion to dismiss posture. White-colored & Situation was the only real firm to possess opposed the grant of certiorari among defense counsel others supported certiorari. On attract the final Court, a legal court rejected the positioning of the Federal trade commission instantly condemning “reverse payment” settlement contracts according to se illegal (the 3rd Circuit position). A legal court held that challenges to such contracts are susceptible to the rule of reason, and we’re presently handling cases for various clients within the lower courts interpreting the final Court’s opinion.
Resourse: https://whitecase.com/law/industries/
